<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414789</url>
  </required_header>
  <id_info>
    <org_study_id>6084</org_study_id>
    <nct_id>NCT02414789</nct_id>
  </id_info>
  <brief_title>Lyme Borreliosis and Early Cutaneous Diagnostic</brief_title>
  <acronym>DIABOLYC</acronym>
  <official_title>Lyme Borreliosis and Early Cutaneous Diagnostic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Test and evaluate a new diagnostic method (SRM-MS/MS: Selected Reaction Monitoring- Mass&#xD;
      spectrometry) for Lyme Borreliosis on human skin biopsies. Patients included are those with&#xD;
      the early skin manifestation (erythema migrans).&#xD;
&#xD;
      This new proteomic method will be compared to the two existing method: culture of Borrelia&#xD;
      and PCR detection of Borrelia (DNA detection of the bacteria).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the sensitivity (percentage of positive tests) of the SRM / MS-MS to techniques of PCR and culture Borrelia</measure>
    <time_frame>One year study</time_frame>
    <description>percentage of positive tests with all three techniques (SRM/MS-MS ; PCR ; culture)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Erythema Migrans</condition>
  <arm_group>
    <arm_group_label>SRM / MS-MS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin biopsies</intervention_name>
    <description>Skin biopsies of patients with Lyme disease (erythema migrans) infected with Borrelia burgdorferi sensu lato will be analyzed by three diagnostic techniques : molecular technique (PCR), biological technique (culture of the bacteria) and proteomics technique (SRM/ MS-MS)</description>
    <arm_group_label>SRM / MS-MS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Erythema migrant as criteria EUCALB or atypical form associated to tick's sting&#xD;
&#xD;
          -  Patient having signed a consent&#xD;
&#xD;
          -  Patient affiliated to a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with antibiotics&#xD;
&#xD;
          -  Erythema migrans on the face&#xD;
&#xD;
          -  Bleeding disorders&#xD;
&#xD;
          -  Anticoagulant treatment&#xD;
&#xD;
          -  Inability to give clear information (subject in an emergency situation, understanding&#xD;
             of the topic difficulty, ...)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Hospitalo-Universitaire Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier William Morey</name>
      <address>
        <city>Chalon-sur-Saône</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital E. Muller</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bel Air</name>
      <address>
        <city>Thionville</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 8, 2015</study_first_submitted>
  <study_first_submitted_qc>April 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2015</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>erythema migrans</keyword>
  <keyword>Lyme</keyword>
  <keyword>early diagnosis</keyword>
  <keyword>skin biomarkers</keyword>
  <keyword>proteomics diagnostic</keyword>
  <keyword>mass spectrometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythema Chronicum Migrans</mesh_term>
    <mesh_term>Lyme Disease</mesh_term>
    <mesh_term>Glossitis, Benign Migratory</mesh_term>
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

